Our group focuses on characterizing the pathophysiological mechanisms involved in the development of insulin resistance, type 2 diabetes, and diabetic kidney disease. We aim to identify novel drug targets and design drug leads for treating type 2 diabetes and its complications. We also study the role of specific proteins as regulators of glomerular ultrafiltration and the molecular mechanisms via which they act.